Intensity Therapeutics (INTS) Announces 3.13M Share Offering at $0.85/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
April 25, 2025 8:00 AM EDTSHELTON, Conn., April 25, 2025 /PRNewswire/ --Â Intensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its "reasonable best efforts" public offering with participation from certain new and existing institutional and accredited investors for... More
